Breaking News, Collaborations & Alliances

Samsung Biologics, BMS Expand Antibody Cancer Drug Agreement

Samsung Biologics will provide drug substance manufacturing for an antibody cancer drug substance.

Samsung Biologics, a contract development and manufacturing organization (CDMO), entered into a new agreement with Bristol Myers Squibb for large-scale manufacturing of a BMS commercial antibody cancer drug substance. BMS and Samsung Biologics have an existing manufacturing agreement for a commercial antibody cancer drug and have expanded the strategic relationship over time. Under the terms of the new agreement, Samsung Biologics will provide drug substance manufacturing for an antibody canc...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters